

# Andrew D Seidman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9646170/publications.pdf>

Version: 2024-02-01

66  
papers

4,267  
citations

201674

27  
h-index

110387

64  
g-index

68  
all docs

68  
docs citations

68  
times ranked

4961  
citing authors

#	ARTICLE	IF	CITATIONS
1	Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab. <i>Npj Breast Cancer</i> , 2022, 8, 37.	5.2	9
2	Randomized Phase II Trial of Proton Craniospinal Irradiation Versus Photon Involved-Field Radiotherapy for Patients With Solid Tumor Leptomeningeal Metastasis. <i>Journal of Clinical Oncology</i> , 2022, 40, 3858-3867.	1.6	47
3	Clinical trial of proton craniospinal irradiation for leptomeningeal metastases. <i>Neuro-Oncology</i> , 2021, 23, 134-143.	1.2	56
4	Comparative Effectiveness Research Needs to Consider Optimal Dosing and Scheduling. <i>Journal of Clinical Oncology</i> , 2021, 39, 253-254.	1.6	1
5	A phase I trial of sorafenib with whole brain radiotherapy (WBRT) in breast cancer patients with brain metastases and a correlative study of FLT-PET brain imaging. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 415-425.	2.5	7
6	Quantitative cerebrospinal fluid circulating tumor cells are a potential biomarker of response for proton craniospinal irradiation for leptomeningeal metastasis. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab181.	0.7	8
7	Cerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptomeningeal metastases in patients with HER2 positive cancer. <i>Journal of Neuro-Oncology</i> , 2020, 148, 599-606.	2.9	50
8	Adjuvant chemotherapy for node negative, high Recurrence Score™ breast cancer: in defense of de-escalation. <i>Npj Breast Cancer</i> , 2019, 5, 24.	5.2	1
9	Examination and prognostic implications of the unique microenvironment of breast cancer brain metastases. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 321-328.	2.5	17
10	Phase I Study of Intermittent High-Dose Lapatinib Alternating with Capecitabine for HER2-Positive Breast Cancer Patients with Central Nervous System Metastases. <i>Clinical Cancer Research</i> , 2019, 25, 3784-3792.	7.0	41
11	“A Tool, Not a Crutch” Patient Perspectives About IBM Watson for Oncology Trained by Memorial Sloan Kettering. <i>Journal of Oncology Practice</i> , 2019, 15, e277-e288.	2.5	28
12	Characteristics and Prognostic Factors for Patients With HER2-overexpressing Breast Cancer and Brain Metastases in the Era of HER2-targeted Therapy: An Argument for Earlier Detection. <i>Clinical Breast Cancer</i> , 2018, 18, 353-361.	2.4	16
13	Phase 2 Study of Dose-Dense Doxorubicin and Cyclophosphamide Followed by Eribulin Mesylate With or Without Prophylactic Growth Factor for Adjuvant Treatment of Early-Stage Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2018, 18, 433-440.e1.	2.4	8
14	Phase II Study of Paclitaxel and Dasatinib in Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2018, 18, 387-394.	2.4	37
15	National Cancer Institute Breast Cancer Steering Committee Working Group Report on Meaningful and Appropriate End Points for Clinical Trials in Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 3259-3268.	1.6	19
16	A phase IIA trial of acupuncture to reduce chemotherapy-induced peripheral neuropathy severity during neoadjuvant or adjuvant weekly paclitaxel chemotherapy in breast cancer patients. <i>European Journal of Cancer</i> , 2018, 101, 12-19.	2.8	72
17	An Important Step Forward for Biosimilars in Cancer Treatment. <i>JAMA Oncology</i> , 2017, 3, 989.	7.1	3
18	Characteristics and Outcomes of Patients With Breast Cancer With Leptomeningeal Metastasis. <i>Clinical Breast Cancer</i> , 2017, 17, 23-28.	2.4	91

#	ARTICLE	IF	CITATIONS
19	In Reply. <i>Oncologist</i> , 2015, 20, 88-88.	3.7	3
20	Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study. <i>Neuro-Oncology</i> , 2015, 17, 289-295.	1.2	149
21	A Pooled Analysis of Gemcitabine Plus Docetaxel Versus Capecitabine Plus Docetaxel in Metastatic Breast Cancer. <i>Oncologist</i> , 2014, 19, 443-452.	3.7	12
22	Outcomes and Prognostic Factors in Women With 1 to 3 Breast Cancer Brain Metastases Treated With Definitive Stereotactic Radiosurgery. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 518-525.	0.8	28
23	Clinical Trials for Breast Cancer with Brain Metastases: Challenges and New Directions. <i>Current Breast Cancer Reports</i> , 2013, 5, 293-301.	1.0	5
24	Randomized Phase II Trial of Weekly vs. Every 2 Weeks vs. Every 3 Weeks Nanoparticle Albumin-Bound Paclitaxel With Bevacizumab as First-Line Chemotherapy for Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2013, 13, 239-246.e1.	2.4	27
25	The Search for an Elusive Uniform Strategy for a Heterogeneous Disease: Lesson Learned?. <i>Journal of Clinical Oncology</i> , 2013, 31, 1707-1708.	1.6	2
26	Electrophysiological Features of Taxane-Induced Polyneuropathy in Patients With Breast Cancer. <i>Journal of Clinical Neurophysiology</i> , 2013, 30, 199-203.	1.7	29
27	Current or recent pregnancy is associated with adverse pathologic features but not impaired survival in early breast cancer. <i>Cancer</i> , 2012, 118, 3254-3259.	4.1	91
28	The Need to Examine Metastatic Tissue at the Time of Progression of Breast Cancer: Is Re-biopsy a Necessity or a Luxury?. <i>Current Oncology Reports</i> , 2011, 13, 17-25.	4.0	32
29	How Long Is Long Enough?. <i>Journal of Clinical Oncology</i> , 2011, 29, 2129-2130.	1.6	3
30	A Feasibility Study of Bevacizumab plus Dose-Dense Doxorubicin+ Cyclophosphamide (AC) Followed by Nanoparticle Albumin-Bound Paclitaxel in Early-Stage Breast Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 3398-3407.	7.0	28
31	Maitake beta-glucan promotes recovery of leukocytes and myeloid cell function in peripheral blood from paclitaxel hematotoxicity. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 885-897.	4.2	17
32	A randomized phase 2 trial comparing 3-hour versus 96-hour infusion schedules of paclitaxel for the treatment of metastatic breast cancer. <i>Cancer</i> , 2010, 116, 814-821.	4.1	23
33	Phase II Trial of Weekly Nanoparticle Albumin-Bound Paclitaxel With Carboplatin and Trastuzumab as First-line Therapy for Women With HER2-Overexpressing Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2010, 10, 281-287.	2.4	86
34	Adjuvant Taxanes: More to the Story. <i>Clinical Breast Cancer</i> , 2010, 10, S41-S49.	2.4	13
35	Concurrent use of chemotherapy or novel agents in combination with radiation in breast cancer. <i>Current Breast Cancer Reports</i> , 2009, 1, 29-41.	1.0	0
36	Beyond Cytotoxic Chemotherapy for the First-Line Treatment of HER2-Negative, Hormone-Insensitive Metastatic Breast Cancer: Current Status and Future Opportunities. <i>Clinical Breast Cancer</i> , 2008, 8, 215-223.	2.4	27

#	ARTICLE	IF	CITATIONS
37	Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840. <i>Journal of Clinical Oncology</i> , 2008, 26, 1642-1649.	1.6	548
38	Taxanes in breast cancer: An update. <i>Current Oncology Reports</i> , 2007, 9, 22-30.	4.0	47
39	Is trastuzumab active following conventional adjuvant chemotherapy in HER2-positive early breast cancer?. <i>Nature Clinical Practice Oncology</i> , 2006, 3, 178-179.	4.3	2
40	Cardiac dysfunction associated with trastuzumab. <i>Expert Opinion on Drug Safety</i> , 2006, 5, 619-629.	2.4	39
41	Systemic treatment of breast cancer. Two decades of progress. <i>Oncology</i> , 2006, 20, 983-90; discussion 991-2, 997-8.	0.5	12
42	Current status of dose-dense chemotherapy for breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2005, 56, 78-83.	2.3	14
43	Paclitaxel, carboplatin, and trastuzumab in HER2-positive metastatic breast cancer. <i>Current Oncology Reports</i> , 2005, 7, 9-11.	4.0	0
44	Development of Inhibitors of HER2 With Taxanes. , 2005, , 175-195.		0
45	Phosphorylated/Activated HER2 as a Marker of Clinical Resistance to Single Agent Taxane Chemotherapy for Metastatic Breast Cancer. <i>Cancer Investigation</i> , 2005, 23, 483-487.	1.3	37
46	Phase II Study of Celecoxib and Trastuzumab in Metastatic Breast Cancer Patients Who Have Progressed after Prior Trastuzumab-Based Treatments. <i>Clinical Cancer Research</i> , 2004, 10, 4062-4067.	7.0	61
47	Gemcitabine and docetaxel in metastatic breast cancer. <i>Oncology</i> , 2004, 18, 13-6.	0.5	28
48	New advances in taxane therapy: the next generation. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2004, 2 Suppl 3, S-5-8.	4.9	0
49	HER2-Positive Breast Cancer. <i>American Journal of Cancer</i> , 2003, 2, 169-179.	0.4	6
50	Monotherapy options in the management of metastatic breast cancer. <i>Seminars in Oncology</i> , 2003, 30, 6-10.	2.2	56
51	Introduction. Single-agent or combination chemotherapy in metastatic breast cancer. <i>Oncology</i> , 2003, 17, 9-14.	0.5	16
52	Single-Agent Capecitabine: A Reference Treatment for Taxane-Pretreated Metastatic Breast Cancer?. <i>Oncologist</i> , 2002, 7, 20-28.	3.7	42
53	Assessment of Molecular Markers of Clinical Sensitivity to Single-Agent Taxane Therapy for Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2002, 20, 2319-2326.	1.6	76
54	Cardiac Dysfunction in Clinical Trials of Trastuzumab. <i>Journal of Clinical Oncology</i> , 2002, 20, 4119-4120.	1.6	5

#	ARTICLE	IF	CITATIONS
55	Introduction. <i>Oncologist</i> , 2002, 7, 1-3.	3.7	2
56	Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience. <i>Journal of Clinical Oncology</i> , 2002, 20, 1215-1221.	1.6	1,006
57	Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel. <i>Clinical Cancer Research</i> , 2002, 8, 670-8.	7.0	60
58	Weekly Trastuzumab and Paclitaxel Therapy for Metastatic Breast Cancer With Analysis of Efficacy by <i>HER2</i> Immunophenotype and Gene Amplification. <i>Journal of Clinical Oncology</i> , 2001, 19, 2587-2595.	1.6	531
59	Oral Gossypol in the Treatment of Patients with Refractory Metastatic Breast Cancer: A Phase I/II Clinical Trial. <i>Breast Cancer Research and Treatment</i> , 2001, 66, 239-248.	2.5	189
60	Lack of Increased Cardiac Toxicity with Sequential Doxorubicin and Paclitaxel. <i>Cancer Investigation</i> , 1998, 16, 67-71.	1.3	9
61	Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing. <i>Journal of Neuro-Oncology</i> , 1997, 35, 47-53.	2.9	167
62	Central nervous system progression of metastatic breast cancer in patients treated with paclitaxel. <i>Cancer</i> , 1995, 76, 232-236.	4.1	104
63	Taxol (paclitaxel): a novel anti-microtubule agent with remarkable anti-neoplastic activity. <i>International Journal of Clinical and Laboratory Research</i> , 1994, 24, 6-14.	1.0	86
64	Immune-mediated thrombocytopenia secondary to suramin. <i>Cancer</i> , 1993, 71, 851-854.	4.1	14
65	Phase II trial of carboplatin and etoposide in metastatic breast cancer. <i>Cancer</i> , 1993, 71, 1254-1257.	4.1	15
66	Taxol and Recombinant Human Granulocyte Colony-Stimulating Factor, an Active Regimen as Initial Therapy for Metastatic Breast Cancer.. <i>Annals of the New York Academy of Sciences</i> , 1993, 698, 398-402.	3.8	1